Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling

ABSTRACT:

Background

Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody-dependent phagocytosis by macrophages. Apoptosis induction is another mechanism of this antibody. Computational docking is the method of predicting the conformation of an antibody-antigen from its separated elements. Validation of the designed antibodies is carried out by docking tools. Increased affinity enhances the biological action of the antibody, which in turn improves the therapeutic effects. Furthermore, the increased antibody affinity can reduce the therapeutic dose of the antib

SUBMITTER: Payandeh Z 

PROVIDER: S-EPMC5889503 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature